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Abstract
Background: Pharmaceutical trials are mainly initiated by sponsors and investigators in the United States, Western Europe
and Japan. However, more and more patients are enrolled in Central and Eastern Europe, Latin America and Asia. The
involvement of patients in new geographical settings raises questions about scientific and ethical integrity, especially when
experience with those settings is lacking at the level of trial management. We therefore studied to what extent the
geographical shift in patient enrolment is anticipated in the composition of trial management teams using the author
nationalities on the primary outcome publication as an indicator of leadership.
Methods and Findings: We conducted a cohort-study among 1,445 registered trials in www.clinicaltrials.gov that could be
matched with a primary outcome publication using clinical trial registry numbers listed in publications. The name of the
sponsor and the enrolment countries were extracted from all registrations. The author-addresses of all authors were
extracted from the publications. We searched the author-address of all publications to determine whether enrolment
countries and sponsors listed on registrations also appeared on a matched publication. Of all sponsors, 80.1% were listed
with an author-address on the publication. Of all enrolment countries, 50.3% appeared with an author-address on the
publication. The listing of enrolment countries was especially low for industry-funded trials (39.9%) as compared to
government (90.4%) and not-for-profit funding (93.7%). We found that listing of enrolment countries in industry-funded
trials was higher for traditional research locations such as the United States (98.2%) and Japan (72.0%) as compared to
nontraditional research locations such as Poland (27.3%) and Mexico (14.1%).
Conclusions: Despite patient enrolment efforts, the involvement of researchers from nontraditional locations in trial
management as measured by their contribution to manuscript writing is modest. This division of labor has significant
implications for the scientific and ethical integrity of global clinical research.
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Introduction
Collaboration and globalization are defining characteristics of
contemporary scientific knowledge production, with the random-
ized clinical trial being a textbook-like example. The conduct of
clinical trials necessitates the collaborative involvement of many
researchers with roles ranging from designing protocols and
enrolling human subjects for data collection to analyzing data
and preparing manuscripts for publication. Standardization and
harmonization of these research practices - as envisaged in the
ICH-GCP guideline – has made the travelling of clinical data
between geographically dispersed research sites less complicated
[1]. This has facilitated globalization of clinical trials with
increasing involvement of researchers from nontraditional
research locations, especially in Central and Eastern Europe,
Latin America and Asia [2,3,4].
However, as clinical trials become ever more global, worries
have been voiced over the division of roles and responsibilities in
those projects. Critics argue that global clinical trials are primarily
conducted for the benefit of a small group of leading scientists and
companies located in the major pharmaceutical markets. Investi-
gators from nontraditional research locations are only hired in
these projects to bring in their patients as ‘experimental subjects’,
without having significant roles in defining research questions,
analyzing the data or drafting manuscripts for publication [1,5,6].
These concerns might be particularly warranted in large scale
multi-center clinical trials that require the appointment of trial
management and evaluation teams such as Executive Committees,
Steering Committees, Data Safety Monitoring Boards and
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Outcome Adjudication Committees. These bodies take overall
responsibility for the integrity of the study and the knowledge
production process and they also have a major stake in writing the
final clinical trial reports for publication.
The constitution of trial management often takes place in
consultation between the sponsor and the first appointed principal
investigator. In principle, membership can be geographically
decoupled from more operational tasks executed at clinical sites.
The quality and integrity of clinical trials may however be
compromised when knowledge of the actual clinical research
situation on the ground is lacking at the level of scientific
management. Geographical differences in the patho-physiology
and behavior of patients may hinder the execution of complex
research protocols, and introduce geographical differences in drug
adherence, drug response, side-effect profiles and ultimately
clinical trial outcomes. At the same time, the integrity of individual
trials may be at stake in the absence of close oversight, especially
when local regulators and health care professionals are less
experienced with clinical trial conduct. In order to enhance the
scientific and ethical integrity of clinical trials, it is thus
recommended that trial management reflects the geographical
diversity of the studied patient populations.
Since there is however no large-scale quantitative data available
on the relation between trial participation and appointment in trial
management, we set out to quantify the extent of this phenom-
enon. More specifically, we study the extent to which authors on
primary outcome publications – as an indicator of trial leadership -
are located in the countries where clinical researchers are involved
with human subjects at clinical sites.
Methods
1. Data collection
Our cohort consists of publications describing the primary
results of clinical trials that are registered on the website www.
clinicaltrials.gov (Figure 1). To establish the link between
registrations and publications, we searched MEDLINE via
PUBMED to find all publications that list a registry number of a
clinical trial (national clinical trial identifier) in the title, abstract or
as a secondary source ID. In order to obtain a sample that only
contains original clinical trial publications, the MEDLINE search
was limited by study type (‘‘clinical trial’’ and ‘‘human’’) and
excluded publications with the following study types or MeSH
terms: ‘‘editorials’’, ‘‘letters’’, ‘‘in vitro’’, ‘‘animal’’, ‘‘review’’,
‘‘meta-analysis’’. We also excluded publications if they made
reference to more than one clinical trial identifier.
Using the trial registry number, the publication sample was
matched with all completed or terminated trials that were
registered in www.clinicaltrials.gov as of January 2011 and set
out to test a drug or a biological. We only focused on trials that
had either a start date after June, 2005 or a completion date after
September, 2005, by which trial registration was mandated by the
International Committee of Medical Journal Editors before onset
[6].
Our prime interest was to determine whether sponsors and
enrolment countries listed on clinical trial registrations were also
listed as authors on a matched outcome publication. To obtain the
sponsors listed on clinical trial registrations we extracted the
sponsor names mentioned in the lead sponsor field of www.
clinicaltrials.gov. To obtain the enrolment countries, we extracted
for every registration all unique countries listed in the study
location field of www.clinicaltrials.gov. Because information in the
study location field was not always reported, we had to exclude
391 protocols. The search matched 1,450 registrations to 1,687
publications (Figure 1).
143 of the 1,450 registrations had a match with more than one
clinical trial publication. As we were interested in the primary
publication following clinical trial conduct, we retrieved the
citation impact scores of all publications from the citation
databank Scopus Elsevier and determined for each registration
which publication received the highest number of citations. We
assumed here that the publication that received the highest
number of citations was the primary outcome publication. In case
two publications received an equal amount of citations, we took
the earliest publication. In addition, we removed an additional 5
publications because they only listed a group-authorship in the
byline of the article.
For the remaining 1,445 publications, all author names were
extracted from both PUBMED and Scopus Elsevier and the
number of authors listed on each publication was compared. In 82
publications there was disagreement between PUBMED and
Scopus Elsevier on the number of authors. This disagreement was
resolved by manually checking the full-text of the article.
We subsequently retrieved the affiliation and country of origin
of all authors that were listed in the address field of the
publications. We downloaded this information from Scopus
Elsevier, which systematically keeps track of address information
of authors. For 226 publications, affiliation or address information
of at least one of the authors was missing. In these cases we
manually retrieved the data from the full-text of the publication.
We were successful in doing this for all but four authors. After
retrieving address information, we listed per publication the name,
organization and country of all 14,298 authors.
2. Analysis
Registrations and publications were 1:1 matched in 1,445
registration-publication pairs. For all registration-publication pairs
we determined whether the enrolment countries on the registra-
tion were mentioned as a country in an author-address on a
matched publication. Based on this information we computed
authorship rates per country which were defined as the percentage
of registered enrolment efforts per country that resulted in an
author-address of that country on a matched publication.
Evidently, the maximum authorship rate of a country is 100
percent, which would indicate that every time a patient from a
particular country is enrolled in a clinical trial, the country is also
represented by an author on a matched publication. We computed
authorship rates for all registrations and broken down by funding
types (i.e. industry, government, other not for profit).
We also determined whether the lead sponsor on the
registration was listed with an author-address on the matched
publication. Next to exact name matches we included for every
affiliation its relevant sub-affiliations. These sub-affiliations
included hospitals with exactly the same name as the university
(and vice versa) and alternative names of the same affiliation. Using
this information, we computed authorship rates of sponsors which
were defined as the proportion of registered sponsors that were
listed with an author-address on a matched publications.
3. Robustness Checks
To ensure that our data is of high quality we conducted three
manual checks on 180 publications in our sample that were
published in the Journal of the American Medical Association or
in the New England Journal of Medicine.
We first compared the reported outcome of the clinical trial in
the publication with the primary outcome as described in the
registration after reading the registration, the abstracts and if
Geography of Leadership in Global Clinical Trials
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necessary the full text of the matched publications. Of the 180
publications, all but one publication reported on the primary
endpoint described in the registration. The single non primary
outcome publication described the result of a secondary endpoint.
We subsequently tested our assumption that authorships on
primary outcome publications are granted to members of trial
management teams. Of 180 publications, 66 publications provided
the names of the management team members who were installed
in an executive committee or steering committee. 76.7% of all
authors on the publications were members of a trial management
team or were affiliated with the sponsor. This percentage was
82.9% when only focusing on industry-funded publications.
Third, we checked the quality of the study location data in the
registrations by comparing it with the provided information on
Figure 1. Inclusion flowchart of sample.
doi:10.1371/journal.pone.0045984.g001
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enrolment efforts in the acknowledgement sections of publications.
In only 1.9% of cases was a country listed on a registration, but not
mentioned in the acknowledgement of the trial publication.
Results
1. Authorship rates by funding type
The 1,445 registrations listed on average 3.4 enrolment
countries in the study location field. In 50.3% of all cases, these
enrolment countries did also appear with an author-address on the
matched publication (Table 1). The extent to which patient
enrolment resulted in authorship on a matched publication was
significantly different between funding sources (p,0.001). For
government and not-for-profit funded clinical trials, enrolment
countries were well represented with authorship rates that
surpassed 90%. In contrast, the authorship rate of enrolment
countries for industry funded trials was 37.8%. Differences in
authorship rates between funding sources were also statistically
significant when focusing on a subset of smaller clinical trials that
recruited in less than five countries (p,0.001, not shown).
Turning to the presence of sponsors on matched publications, in
more than 80% of all publications the sponsor became an author
on a subsequent publication (Table 1). This percentage was
particular high for industry funded clinical trials (83.2%) and other
not-for- profit funded clinical trials (84.9%), in comparison to
government funded clinical trials (40.0%).
2. Authorship rates per country
The extent to which patient enrolment resulted in authorship on
a matched publication was unevenly distributed between countries
(Figure 2). As shown in Table 1, low authorship rates were mainly
visible in industry-funded research and we therefore report
country-specific results for this subset of registration-publication
pairs in Table 2. Reading from Table 2, the United States was an
enrolment country in 399 clinical trials. In 392 of these clinical
trials an author-address from the United States appeared on a
matched publication, resulting in an authorship rate of 98.2%. In
contrast, 92 clinical trials included Mexico as an enrolment
country, but an author from Mexico appeared on only 13 matched
publications which resulted in an authorship rate of 14.1%. More
in general, traditional research locations had the highest author-
ship rates starting with the United States (98.2%) and followed by
Japan (72.0%), Germany (68.0%) and United Kingdom (64.8%).
Although enrolment activities were substantial in nontraditional
research locations, these countries showed relatively low author-
ship rates judged for instance by the authorship rates of Poland
(27.3%), Czech Republic (23.3%), Argentina (24.1%) and South
Africa (22.5%).
3. Exclusion of author-addresses of sponsors
A reason behind the high authorship rates of traditional
research locations might be that pharmaceutical companies are
more often located in those countries. This might have biased our
results towards countries that host many pharmaceutical compa-
nies, because authors from these companies were also often
represented on matched publications. We therefore controlled for
this in the second set of columns in Table 2, where we assessed
authorship rates of enrolment countries, after removing all
addresses of authors affiliated to sponsors from the matched
publications. This rendered only a minor decrease in the overall
authorship rate of countries and did not change the main
observation. For instance, the authorship rate of the United
Kingdom was 64.8% when considering all authors on matched
publications and 60.6% with the exclusion of author-addresses of
sponsors. More specifically, the United Kingdom was listed as an
enrolment country on 142 registrations and appeared with an
author-address on 92 matched publications, which was nearly
similar as the 86 matched publications when excluding author-
addresses of sponsors. In general, when excluding author-
addresses of sponsors, authorship rates remained high for countries
that hosted many pharmaceutical companies and for traditional
research locations when compared to nontraditional research
locations.
Discussion
This study showed that although clinical trial activities are now
executed across the globe, scientific leadership in these trials is
disproportionally concentrated in traditional research locations.
This geographical decoupling of patient enrolment and clinical
trial management is most pronounced in industry funded research.
Although we did not empirically investigate the reasons for this
phenomenon, we provide three explanations and their implica-
tions below.
First, the appointment in trial management teams is dependent
on the social structure in which the activities of sponsors and
principal investigators are embedded. Authorships of researchers
who hold central positions in scientific networks are likely to boost
the credibility and dissemination of clinical trial results. It follows
that researchers with well-established reputations and affiliations
to renowned medical institutes (so-called key opinion leaders)
become more likely to be part of management teams than clinical
investigators from nontraditional research locations [7]. Over
time, these social network structures will be strengthened by the
development of trust based relations that facilitate repetition of
existing social ties [8,9]. Given these social network dynamics, the
observed geography of scientific leadership becomes performative,
Table 1. Number of authors and authorship rates of sponsors and countries.
Total Industry Government Other not for profit p-value
Registration-Publications, n (%) 1445 (100.0%) 650 (45.0%) 130 (9.0%) 665 (46.0%)
Authors, mean (SD) 9.9 (5.4) 9.8 (5.3) 11.6 (6.3) 9.7 (5.3) ,0.001
Enrolment countries, mean (SD) 3.4 (6.2) 6.1 (8.5) 1.2 (0.5) 1.2 (1.2) ,0.001
Authorship rate of countries*, % 50.3% 39.9% 90.4% 93.7% ,0.001
Autorship rate of sponsors{, % 80.1% 83.2% 40.0% 84.9% ,0.001
P-values for differences between funding types.
*The authorship rate of countries is defined as the percentage of registered enrolment countries that are listed with an address on a matched publication.
{The authorship rate of sponsors is defined as the percentage of registered sponsors that are listed with an affiliation on a matched publication.
doi:10.1371/journal.pone.0045984.t001
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as the key roles of researchers in traditional research locations are
‘confirmed’ over and over again at the expense of the roles of
researchers in nontraditional research locations.
Second, the structure of clinical trial management might be
driven by considerations of efficiency among team members.
Despite recent advances in information and communication
technologies, face-to-face interaction remains important to carry
out the complex tasks associated with scientific research [10,11].
Accordingly, in selecting clinical trial leaders, pharmaceutical
companies might have a preference for researchers that are
proximate to them both in geographical terms and on other
dimensions, as proximity facilitates efficient communication
among team members and decreases coordination costs [12].
Third, from an organizational perspective, relations between
clinical investigators in nontraditional research locations and
clinical trial management teams might be mediated by a Contract
Research Organization (CRO). Pharmaceutical companies in-
creasingly outsource the operational aspects of clinical trials to
CROs who negotiate contracts with clinical sites and monitor data
production [13,14]. The use of CROs creates a relatively distant
relation between the management team that initiates and designs
the trial and the clinical investigators at study sites. Hence, in
outsourced clinical trials the role of clinical investigators in other
tasks than patient enrolment is frequently modest.
All three arguments point towards distant connections between
the researchers that enroll patients and the researchers that
produce clinical knowledge for publications. This has implications
for the integrity of individual clinical trials and the clinical research
enterprise as a whole. With regard to the integrity of individual
clinical trials an important implication follows from the increased
diversity of patients and their habits in global clinical trials. It is
well known that responses to treatment differ considerably
between patients according to local diets, drug adherence, body
sizes, genetic makeup and the local health care delivery system
[1,5]. Proper interpretation of data therefore necessitates close
interactions between those researchers that are in immediate
contact with patients and researchers that design trials and
interpret clinical trial results. The transfer of context specific
knowledge may therefore be best served by increased leadership
for researchers from nontraditional research locations. They can
create awareness about local specificities and may stimulate debate
about the extent to which the findings of clinical trials are
generalizable to varying populations across the globe.
Another implication relates to the quality of data that follows
from globalized clinical trial conduct. Although it is difficult to
make definitive statements here, physicians and researchers from
nontraditional countries are often trained in different contexts and
are generally less experienced in conducting clinical trials. In
addition, they are often not involved in the final knowledge
production process and do not always have access to the data they
collected [14,15,16]. These circumstances may lower their
incentive to be accurate in data-collection. Rigorous training of
local researchers and increased engagement at leadership level can
improve data quality because researchers are made accountable
for the final scientific evidence that is produced. Indeed these
measures should be taken in addition to strict independent
monitoring and regulatory oversight of clinical sites, which is
under increasing pressure as indicated by the observation that the
FDA inspected only 0.7% of all foreign clinical trial sites in 2008
[17].
A final implication concerns the transparency of global clinical
trials. Globalization has made the conduct of clinical trials more
decentralized, and it has become difficult to monitor its rapidly
changing geography [1]. In this respect, specific worries have been
Figure 2. Authorship rates per country for all registrations (n=1,445).
doi:10.1371/journal.pone.0045984.g002
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Table 2. Number of registrations and authorship rates for industry-funded trials per country for all authors and when excluding
author-addresses of sponsors.
Authorship rates
Country Number of registrations All authors excluding author-addresses of sponsors
United States 399 392 (98.2%) 370 (92.7%)
Germany 194 132 (68.0%) 128 (66.0%)
Canada 171 102 (59.6%) 100 (58.5%)
France 165 95 (57.6%) 93 (56.4%)
Spain 146 57 (39.0%) 57 (39.0%)
United Kingdom 142 92 (64.8%) 86 (60.6%)
Italy 127 54 (42.5%) 53 (41.7%)
Belgium 119 43 (36.1%) 41 (34.5%)
Netherlands 115 47 (40.9%) 46 (40.0%)
Australia 110 40 (36.4%) 39 (35.5%)
Poland 110 30 (27.3%) 30 (27.3%)
Sweden 97 40 (41.2%) 36 (37.1%)
Mexico 92 13 (14.1%) 13 (14.1%)
Denmark 91 43 (47.3%) 39 (42.9%)
Czech Republic 90 21 (23.3%) 21 (23.3%)
Argentina 87 21 (24.1%) 21 (24.1%)
Russia 85 19 (22.4%) 19 (22.4%)
Brazil 84 24 (28.6%) 24 (28.6%)
South Africa 80 18 (22.5%) 18 (22.5%)
Hungary 71 11 (15.5%) 11 (15.5%)
Austria 69 14 (20.3%) 14 (20.3%)
Finland 69 16 (23.2%) 16 (23.2%)
Switzerland 69 25 (36.2%) 18 (26.1%)
Norway 65 11 (16.9%) 11 (16.9%)
Greece 58 7 (12.1%) 7 (12.1%)
China 57 27 (47.4%) 27 (47.4%)
South Korea 54 13 (24.1%) 13 (24.1%)
India 53 16 (30.2%) 16 (30.2%)
Israel 49 8 (16.3%) 8 (16.3%)
Romania 49 8 (16.3%) 8 (16.3%)
Taiwan 47 13 (27.7%) 13 (27.7%)
Puerto Rico 46 8 (17.4%) 8 (17.4%)
Portugal 45 5 (11.1%) 5 (11.1%)
Turkey 43 8 (18.6%) 8 (18.6%)
Slovakia 42 6 (14.3%) 6 (14.3%)
Chile 40 1 (2.5%) 1 (2.5%)
Bulgaria 35 4 (11.4%) 3 (8.6%)
New Zealand 31 7 (22.6%) 7 (22.6%)
Singapore 31 5 (16.1%) 5 (16.1%)
Ireland 29 3 (10.3%) 2 (6.9%)
Malaysia 26 4 (15.4%) 4 (15.4%)
Thailand 26 5 (19.2%) 5 (19.2%)
Japan 25 18 (72.0%) 18 (72.0%)
Ukraine 25 1 (4.0%) 1 (4.0%)
Lithuania 23 3 (13.0%) 3 (13.0%)
Geography of Leadership in Global Clinical Trials
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voiced over the relative invisibility of nontraditional research
locations in the clinical trial enterprise [5,6]. Efforts to increase
transparency by listing information on enrolment efforts in
registrations and publications constitute important steps to change
this situation. The recording of enrolment efforts can potentially
go beyond the current state to include the names of clinical
researchers, the organization that recruit patients and the
(expected) number of patients that are recruited per study location.
These forms of transparency will make both sponsors and local
researchers more accountable for the choices they make and their
subsequent performance [18].
Increased transparency about enrolment efforts and the equal
inclusion of researchers in clinical trial management is an
important step to steer clinical research in a direction where it
serves the health needs of communities across the globe. The
globalization of clinical trials has raised many ethical concerns
including the ethical standards of care that should be provided to
patients, obtaining informed consent from illiterate patients and
the provision of treatments to patients after the study has ended. It
seems in the best interest of patients that researchers from
nontraditional research locations have a clear voice in these issues
when clinical trials are designed and conducted and when their
results are interpreted. This will raise more awareness of the
promises and pitfalls of realizing inclusive evidence-based medi-
cine that is to the benefit of patients and researchers across the
globe.
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